empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
Decreases aspartate aminotransferase
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Meta-analysis concluded that empagliflozin was able to decrease AST levels among patients suffering from NAFLD compared with controls; the statistical difference was significant (MD: −3.10, 95% CI: −6.18 to −0.02, p = 0.05, I2 = 0%).”
Quoted verbatim from Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Population
- Patients with NAFLD, pooled across randomized trials of empagliflozin 20 to 24 weeks; control arms were mostly placebo with one glimepiride arm
Effect -3.1 mean difference, 95% CI -6.18 to -0.02
Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.2022PMID:35282455Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against Aspartate aminotransferase
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M4PR747MXH605PY2EHRHMQPR